Enanta Pharmaceuticals | ENTA - Zinsaufwendungen Für Schuld

Aktienkurs
14.11
Täglich Wechseln
0.16 1.15%
Monatlich
-0.42%
Jährlich
200.85%
Q2 Prognose
13.72




Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 740M 40M 2025-06
Amgen USD 653M 32M 2025-12
Anika Therapeutics 189.44M 1.76M 2025-09
Arrowhead Research USD 22.5M 811K 2025-12
AstraZeneca USD 484M 181M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 432M 48M 2025-12
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 188M 21M 2025-12
Halozyme Therapeutics USD 4.91M 615K 2025-12
Heron Therapeutics USD 600K 100K 2024-12
Immunic 400K 400K 2024-12
Incyte USD 582K 10K 2025-12
Insmed USD 20.6M 217K 2025-12
Ionis Pharmaceuticals USD 18M 0 2025-12
J&J USD 18M 290M 2025-09
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
Ligand Pharmaceuticals USD 910K 243K 2025-09
Merck USD 412M 85M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 304M 23M 2025-12
Novavax USD 5.82M 342K 2025-12
Pfizer USD 711M 59M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Vertex Pharmaceuticals USD 3.3M 0 2025-12